Association of Concomitant Proton Pump Inhibitor Use with Survival Outcomes During CDK4/6 Inhibitor Therapy for Breast Cancer
BACKGROUND: Concomitant use of proton pump inhibitors (PPIs) is common during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy. We examined the association between concomitant PPI use and survival outcomes in patients with hormone receptor-positive, HER2-negative breast cancer. METHODS: We conducted a nationwide retrospective cohort study using Korean National Health Insurance Service data. PPI exposure was defined as at least 30 days of overlapping PPI and CDK4/6 inhibitor prescriptions during the first 90 days after CDK4/6 inhibitor initiation. Patients who died or experienced a real-world progression-free survival (rwPFS) event during this window were excluded. Follow-up for rwPFS and overall survival (OS) began at day 90. We used stabilized inverse probability of treatment weighting and weighted Cox models to estimate hazard ratios (HRs). RESULTS: Of 7,208 patients who initiated CDK4/6 inhibitor therapy, 6,435 entered the landmark cohort, including 574 (8.9%) who met the PPI exposure definition. After weighting, absolute standardized mean differences were below 0.10 for all included covariates. Concomitant PPI use was associated with shorter rwPFS (HR, 1.33; 95% confidence interval [CI], 1.16-1.51) and OS (HR, 1.54; 95% CI, 1.34-1.76). The unweighted estimates were in the same direction (rwPFS HR, 1.32; OS HR, 1.65). CONCLUSIONS: Concomitant PPI use was associated with shorter rwPFS and OS among patients who remained alive and event-free through day 90. Residual confounding, including differences in the indications for PPI use, may contribute to these associations. Further studies are needed to clarify their clinical significance.
Authors
- Jeong Won Jin
- Sungmin Park
- Kyung-Hun Lee
- Ji Sung Lee
Institutions
- Cancer Research Institute (US)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- Chungbuk National University Hospital (KR)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1093/oncolo/oyag463
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00